NM_018206.5(VPS35):c.1858G>A (p.Asp620Asn) AND Parkinson disease 17

Clinical significance:Pathogenic (Last evaluated: Oct 1, 2012)

Review status:(0/4) 0 stars out of maximum of 4 stars

no assertion criteria provided

Based on:
1 submission [Details]
Record status:
current
Accession:
RCV000023115.5

Allele description [Variation Report for NM_018206.5(VPS35):c.1858G>A (p.Asp620Asn)]

NM_018206.5(VPS35):c.1858G>A (p.Asp620Asn)

Gene:
VPS35:VPS35, retromer complex component [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
16q11.2
Genomic location:
Preferred name:
NM_018206.5(VPS35):c.1858G>A (p.Asp620Asn)
HGVS:
  • NC_000016.10:g.46662452C>T
  • NG_029970.1:g.31781G>A
  • NM_018206.5:c.1858G>A
  • NP_060676.2:p.Asp620Asn
  • NC_000016.9:g.46696364C>T
  • NM_018206.4:c.1858G>A
  • Q96QK1:p.Asp620Asn
Protein change:
D620N; ASP620ASN
Links:
UniProtKB: Q96QK1#VAR_066659; OMIM: 601501.0001; dbSNP: 188286943
NCBI 1000 Genomes Browser:
rs188286943
Molecular consequence:
  • NM_018206.5:c.1858G>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Parkinson disease 17 (PARK17)
Identifiers:
MedGen: C3280133; Orphanet: 411602; OMIM: 614203
Age of onset:
Adult

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000044406OMIMno assertion criteria providedPathogenic
(Oct 1, 2012)
germlineliterature only

PubMed (5)
[See all records that cite these PMIDs]

Vilarino-Guell, C., Wider, C., Ross, O. A., Dachsel, J. C., Kachergus, J. M., Lincoln, S. J., Soto-Ortolaza, A. I., Cobb, S. A., Wilhoite, G. J., Bacon, J. A., Behrouz, B., Melrose, H. L., and 21 others VPS35 mutations in Parkinson disease. Am. J. Hum. Genet. 89: 162-167, 2011. Note: Erratum: Am. J. Hum. Genet. 89: 347 only, 2011.

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlinenot providednot providednot providednot providednot providednot providedliterature only

Citations

PubMed

Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family.

Wider C, Skipper L, Solida A, Brown L, Farrer M, Dickson D, Wszolek ZK, Vingerhoets FJ.

Parkinsonism Relat Disord. 2008 Aug;14(6):465-70. doi: 10.1016/j.parkreldis.2007.11.013. Epub 2008 Mar 14.

PubMed [citation]
PMID:
18342564

A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease.

Zimprich A, Benet-Pag├Ęs A, Struhal W, Graf E, Eck SH, Offman MN, Haubenberger D, Spielberger S, Schulte EC, Lichtner P, Rossle SC, Klopp N, Wolf E, Seppi K, Pirker W, Presslauer S, Mollenhauer B, Katzenschlager R, Foki T, Hotzy C, Reinthaler E, Harutyunyan A, et al.

Am J Hum Genet. 2011 Jul 15;89(1):168-75. doi: 10.1016/j.ajhg.2011.06.008.

PubMed [citation]
PMID:
21763483
PMCID:
PMC3135812
See all PubMed Citations (5)

Details of each submission

From OMIM, SCV000044406.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedliterature only PubMed (5)

Description

By exome sequencing of affected members of a Swiss family with autosomal dominant Parkinson disease-17 (PARK17; 614203) reported by Wider et al. (2008), Vilarino-Guell et al. (2011) identified a heterozygous 1858G-A transition in the VPS35 gene, resulting in an asp620-to-asn (D620N) substitution in a highly conserved residue. Subsequent sequencing of this gene in 4,326 PD patients identified 4 more with the same mutation: 3 familial cases and 1 with sporadic disease. Haplotype analysis indicated independent mutational events, suggesting a mutational hotspot. The mutation was not found in 3,309 controls. The average age at onset was 50.6 years, and patients had tremor-predominant, levodopa-responsive parkinsonism.

Simultaneously and independently, Zimprich et al. (2011) used exome sequencing to identify the D620N mutation in affected members of a large Austrian family with autosomal dominant parkinsonism. The mutation occurred in exon 15 of the gene. Two additional carriers of this mutation were found among 486 PD patients in Austria. Age-dependent incomplete penetrance was observed.

By specific screening for the D620N mutation among Japanese patients with Parkinson disease, Ando et al. (2012) identified the heterozygous mutation in 3 (1.0%) of 330 patients with autosomal dominant PD and in 1 (0.23%) of 433 patients with sporadic PD. Haplotype analysis suggested at least 3 independent founders in this population, indicating that it may be a mutational hotspot. Patients with this mutation showed typical adult-onset, tremor-predominant PD with good response to levodopa treatment. The mutation was not found in 1,158 control chromosomes.

Lesage et al. (2012) identified a heterozygous D620N mutation in 3 (1.2%) of 246 mostly French probands with autosomal dominant typical PD. All 3 index patients were of French origin, and the mutation was shown to segregate with the disorder in 1 family; segregation analyses were not available for the 2 remaining families. Two of the French families shared a common haplotype. The mutation was not found in 245 European controls, and no additional pathogenic VPS35 variants were identified.

By targeted sequencing, Kumar et al. (2012) identified a heterozygous VPS35 D620N mutation in 1 of 1,774 patients with Parkinson disease. The patients were ascertained from several tertiary referral centers in Germany, Serbia, Chile, and the United States. The patient with the mutation was a German man who developed typical PD at age 45 years. Family history revealed an affected paternal aunt who carried the mutation, as well as 3 reportedly unaffected sibs in their fifties and sixties who also carried the mutation, indicating incomplete penetrance. Kumar et al. (2012) concluded that VPS35 mutations are a rare cause of PD, and they estimated a carrier frequency for the D620N mutation of 0.1% among patients with PD.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlinenot providednot providednot providednot providednot providednot providednot providednot provided

Last Updated: May 8, 2017